MYLK and breast cancer: In addition to our discovery of a potential panel of genes for BC, the genes we found that modulate smooth muscular contraction (ACTA2, ATP1A2, CALD1, CAV1, EDNRA, GJA1, LMOD1, MYH11, MYLK, TPM1, TPM2, and VIM) could represent potential therapeutic targets for the treatment of diseases related to bladder contraction [15].